July 13, 2020

The Future of Prostate Cancer Screening Is Here

When it comes to more accurate diagnosis, IsoPSA® offers better insights and a little more hope

Prostate organ by the bladder

Next to skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society® has estimated that there will be around 192,000 new cases of prostate cancer and close to 33,330 deaths from it this year.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Prostate cancer typically occurs in men over 50 and is most commonly diagnosed in men in their 70s. And according to the National Cancer Institute, African-American men are more likely to die from this disease than any other racial group.

But prostate cancer isn’t a death sentence

The American Cancer Society® reports that more than 3.1 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

Most newly diagnosed prostate cancer is considered low-grade (where tumors grow slowly and rarely spread) and only needs to be monitored using a strategy called active surveillance. On the other hand, more aggressive cancers can grow and spread. But if caught early, these cancers are easy to treat.

Why prostate cancer screenings are important

Since most men who have localized prostate cancer don’t have any symptoms, screenings can help catch it earlier so it can be treated before it spreads. Prostate-specific antigen (PSA) prostate cancer screenings have been shown to reduce the likelihood of dying from prostate cancer.

General prostate screening guidelines

The American Cancer Society® offers these age and risk guidelines for prostate cancer screenings, using the PSA blood test:

  • Age 50 for men who are at average risk of prostate cancer and are expected to live at least 10 more years.
  • Age 45 for men at high risk of developing prostate cancer. This includes African Americans and men who have a first-degree relative (father or brother) diagnosed with prostate cancer at an early age (younger than age 65).
  • Age 40 for men at even higher risk (those with more than one first-degree relative who had prostate cancer at an early age).

What is a PSA test?

PSA is a protein that can be produced by normal and malignant cells in the prostate gland. A PSA test is a way to determine how much of this protein is present in a man’s blood. An elevated level of PSA is frequently due only to noncancerous prostate enlargement, but it can indicate the presence of prostate cancer.

Advertisement

The trouble with PSA testing

“PSA testing has been shown to reduce the death rate due to prostate cancer in men who are screened and to reduce the need for treatment of metastatic disease,” says urologic oncologist Eric Klein, MD. “However, it has some limitations. One limitation is that it can’t distinguish between non-cancerous prostate enlargement, which is the most common reason a PSA might go up, and prostate cancer.”

The development of the IsoPSA® test

In 2015, the Cleveland Clinic partnered with Cleveland Diagnostics, Inc. to develop a more comprehensive PSA test. The test, known as IsoPSA®, can help zero in on molecular structural changes in PSA protein instead of just focusing on the concentration of PSA in the blood. Dr. Klein explains.

“IsoPSA® is a test that has better accuracy for predicting whether or not someone has prostate cancer that needs treatment. When it’s used clinically and we have a worrisome PSA — where it’s not clear whether a case involves non-cancerous prostate enlargement or prostate cancer, IsoPSA® can help physicians determine whether or not a biopsy is necessary. If the test is used as intended, many men who would normally undergo a biopsy will be able to avoid one.”

The studies have been promising

A preliminary study from 2017 showed that IsoPSA® outperformed traditional PSA testing in predicting the overall risk of prostate cancer and the risk of clinically significant cancer. For this study, the test was given to 261 men who were scheduled for prostate biopsies at five U.S. academic and community centers between August 2015 and December 2016.

A validation study published in 2019 revealed that when used in a clinical setting, IsoPSA® could reduce unnecessary prostate biopsies by more than 40% while reliably determining the presence of high-grade disease.

The false-negative rate for IsoPSA® was very low, and the test’s ability to identify high-grade tumors when used in addition to multiparametric magnetic resonance imaging (mpMRI)-guided biopsy could help healthcare providers develop stronger diagnostic regimens for those with prostate cancer.

Advertisement

IsoPSA® has been fast-tracked by the FDA

IsoPSA® received breakthrough device designation from the U.S. Food & Drug Administration in late 2019. This distinction is expected to help speed up the regulatory process so that the test can be made widely available.

What’s next for IsoPSA®?

As for now, IsoPSA® will be implemented at the Cleveland Clinic health system’s Ohio locations. Dr. Klein and his team will be examining best practices and efficiencies for the test’s clinical application and trial process. He is excited about what IsoPSA® can offer providers and patients because when it’s used correctly, the test can provide important data that makes the conversation about prostate cancer biopsies a little easier.

“People are excited by this,” says Dr. Klein. “The science behind IsoPSA® is different from other tests on the market. That’s what makes it so thrilling. We believe that IsoPSA® is a better measure of the biology of prostate cancer, and that may make it more accurate.”

Related Articles

Male eating a vegan meal.
September 5, 2022
Is a Vegan Diet Good for Prostate Health?

Research shows that eating more plant-based food may reduce your risk of prostate cancer

Gloved hand holds a Prostate-Specific Antigen Test
December 20, 2021
Should You Take a PSA Test for Prostate Cancer?

This simple blood test can be key to early detection

Can Ultrasound Help You Fight Prostate Cancer — and Avoid Surgery?
April 11, 2021
Can Ultrasound Help You Fight Prostate Cancer — and Avoid Surgery?

High-intensity focused ultrasound (HIFU) provides new treatment options

Using the MRI to pinpoint prostate problem areas
September 17, 2019
Are MRI Fusion Biopsies Better at Detecting Prostate Cancer Than Conventional Biopsies?

MRI improves detection, but it's not yet a substitute for standard biopsy

woman with metastatic breast cancer at office desk
March 8, 2024
Working While Living With Metastatic Breast Cancer

Working has its benefits, but it may require some modifications — and that’s OK

Woman and physician discuss medical result in office setting
March 8, 2024
How Palliative Care Can Help if You’re Living With Metastatic Breast Cancer

Palliative care offers a comprehensive network of support at any stage, from diagnosis to treatment and beyond

smiling healthcare provider speaking with smiling patient
March 6, 2024
Here’s Why Ulcerative Colitis and Crohn’s Disease Increase Your Risk of Colon Cancer

Chronic inflammation from flare-ups can damage the lining of your intestinal wall, making your colon more vulnerable to cancer

Healthcare provider in surgical gloves and gown holding endoscope
March 5, 2024
Colorectal Cancer Screenings: Endoscopy vs. Colonoscopy vs. Sigmoidoscopy

Colonoscopies and sigmoidoscopies are types of endoscopies, procedures that look at the health of your large intestine

Trending Topics

White bowls full of pumpkin seeds, dark chocolate and various kinds of nuts
25 Magnesium-Rich Foods You Should Be Eating

A healthy diet can easily meet your body’s important demands for magnesium

Woman feeling for heart rate in neck on run outside, smartwatch and earbuds
Heart Rate Zones Explained

A super high heart rate means you’re burning more than fat

Spoonful of farro salad with tomato
What To Eat If You’ve Been Diagnosed With Prediabetes

Type 2 diabetes isn’t inevitable with these dietary changes

Ad